31st May 2016
Cancer Research Technology (CRT), which is the development arm of the UK research charity has formed a partnership with Spanish firm Pangaea Biotech to develop inhibitor drugs for cancer.
These medicines look to be promising and have been developed by scientists at CRT's Discovery Laboratories with support from King's College London.
Known as PAK inhibitors, the drugs are concerned with cell growth and survival and are over-expressed in several cancers, including ovarian, breast, pancreatic and lung, among others.
It is hoped that with these PAK inhibitors that they'll block the activity of over-expressed PAK protein, in other words they'll be able to kill cancer cells.
Under the new partnership, Pangaea Biotech will be responsible for the research and development of the PAK inhibitors.
Javier Rivela, chief executive officer of Pangaea Biotech, said: "We are excited about this partnership, as it marks the beginning of what we expect to be a fruitful long-term collaboration with one of the most important global buyers in cancer drug development."
Posted by Jeanette Royston
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.